{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"71.6","value":"20.0"},{"groupId":"OG001","lowerLimit":"9.9","upperLimit":"81.6","value":"42.9"},{"groupId":"OG002","lowerLimit":"0.5","upperLimit":"71.6","value":"20.0"},{"groupId":"OG003","lowerLimit":"4.3","upperLimit":"77.7","value":"33.3"},{"groupId":"OG004","lowerLimit":"29.9","upperLimit":"70.1","value":"50.0"},{"groupId":"OG005","lowerLimit":"18.6","upperLimit":"47.6","value":"31.8"},{"groupId":"OG006","lowerLimit":"27.2","upperLimit":"51.0","value":"38.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"44"},{"groupId":"OG006","value":"70"}],"units":"Participants"}],"description":"Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central laboratory. Complete remission (CR) was defined as\n\n* M1 bone marrow (bone marrow blasts \\< 5%)\n* No evidence of circulating blasts or extra-medullary disease\n\nComplete remission includes participants with incomplete recovery of peripheral blood counts.","dispersionType":"95% Confidence Interval","groups":[{"description":"Blinatumomab was administered as a continuous intravenous (cIV) infusion at a constant daily flow rate of 5 µg/m²/day over 4 weeks followed by a treatment-free interval of 2 weeks for up to five cycles of treatment.","id":"OG000","title":"Phase 1: Blinatumomab 5 µg/m²/Day"},{"description":"Blinatumomab was administered as a continuous intravenous infusion at a constant daily flow rate of 15 µg/m²/day over 4 weeks followed by a treatment-free interval of 2 weeks for up to five cycles of treatment.","id":"OG001","title":"Phase 1: Blinatumomab 15 µg/m²/Day"},{"description":"Blinatumomab was administered as a continuous intravenous infusion at a constant daily flow rate of 30 µg/m²/day over 4 weeks followed by a treatment-free interval of 2 weeks for up to five cycles of treatment.","id":"OG002","title":"Phase 1: Blinatumomab 30 µg/m²/Day"},{"description":"Blinatumomab was administered as a continuous intravenous infusion at a constant daily flow rate of 15 µg/m²/day for the first week of cycle 1 and then at 30 µg/m²/day for 3 weeks followed by a treatment-free interval of 2 weeks. Participants received subsequent cycles at 30 µg/m²/day for up to five cycles of treatment.","id":"OG003","title":"Phase 1: Blinatumomab 15/30 µg/m²/Day"},{"description":"Blinatumomab was administered as a continuous intravenous infusion at a constant daily flow rate of 5 µg/m²/day for the first week of cycle 1 and then at 15 µg/m²/day for 3 weeks followed by a treatment-free interval of 2 weeks. Participants received subsequent cycles at 15 µg/m²/day for up to five cycles of treatment.","id":"OG004","title":"Phase 1: Blinatumomab 5/15 µg/m²/Day"},{"description":"Blinatumomab was administered as a continuous intravenous infusion at a constant daily flow rate of 5 µg/m²/day for the first week of cycle 1 and then at 15 µg/m²/day for 3 weeks followed by a treatment-free interval of 2 weeks. Participants received subsequent cycles at 15 µg/m²/day for up to five cycles of treatment.","id":"OG005","title":"Phase 2: Blinatumomab 5/15 µg/m²/Day"},{"description":"Blinatumomab was administered as a continuous intravenous infusion at a constant daily flow rate of 5 µg/m²/ day for the first week of cycle 1 and then at 15 µg/m²/day for 3 weeks followed by a treatment-free interval of 2 weeks. Participants received subsequent cycles at 15 µg/m²/day for up to five cycles of treatment.","id":"OG006","title":"Phase 1+2: Blinatumomab 5/15 µg/m²/Day"}],"paramType":"NUMBER","populationDescription":"The full analysis set includes all participants who received any infusion of blinatumomab.","reportingStatus":"POSTED","timeFrame":"Cycles 1 and 2 (12 weeks)","title":"Percentage of Participants With Complete Remission in the First Two Cycles","type":"PRIMARY","unitOfMeasure":"percentage of participants"}